As an expert with 20 years of experience in novel drug development, I firmly believe that tumor organoids are an innovative technology enabling accurate evaluation by comparing patient-derived cancer and normal cells. They offer significantly higher precision in drug assessment than traditional cell and animal models. Additionally, organoids allow the observation of patient-specific drug responses, making them invaluable for clinical trial design and biomarker development. Using organoid efficacy evaluations, I have advanced immunotherapy to clinical trials and obtained intriguing results with novel modality drug validation. I highly recommend leveraging the organoid platform in your work.